Which drugs are driving spending up?
Prescription spending climbs every year, but the headline number never says why. The public records hold what each drug costs, how many people fill it, and how all of that changed from last year. The problem is that the records are built for looking up one drug at a time, not for ranking thousands of them or pulling apart the cause. Asked properly, they split the two stories that get blended together: drugs that simply cost more per fill, and drugs that just got prescribed to more people.
The total spending hides why it grew.
The records carry everything needed to explain why spending on a drug changed, the total spent, how many prescriptions were filled, how many people took it, the cost per fill and per person, how all of that moved from last year, and the company behind each drug. The catch is that they're built for browsing one drug at a time, not for ranking thousands of them or pulling growth apart into its causes, which is why the useful question, what actually drove the increase, usually goes unasked.
Made easy to ask, the answer is direct. A drug's spending can rise because the price per fill went up, because more people used it, or both, and the per-fill and per-person figures next to the totals let you tell which. You can rank every drug by how much it added to the year's growth, label it as price or more patients, and trace it back to the maker, all in one pass.
Questions you can finally ask.
Each is a question you simply ask and get an answer to, not a three-week analysis project.
Which drugs added the most spending this year?
Rank every drug by how many dollars it added to this year's growth, so the real cost drivers surface instead of the loudest headlines.
Was a drug's growth price or more patients?
Split each increase into cost per fill versus how many people used it, to see which one drove the change.
Which drugs got more expensive per fill?
Sort by the change in cost per fill to isolate pure price movement, setting usage aside.
Which makers drive the most spending?
Roll spending and growth up by company to see which makers account for the largest share of the cost.
Where is spending high but few people benefit?
Find drugs with huge total spending but very few patients, the high-cost, low-volume specialty products.
Which drugs are quietly scaling in usage?
Surface drugs growing fast on patient count even when the per-fill price is flat, the volume stories the price debate misses.
What the answer pulls together.
What was spent and how much it was used
Total spending, prescriptions filled, and how many people took each drug, the raw scale of what was paid for.
Cost per fill and per person
The average cost per prescription and per patient, the figures that separate a price story from a more-patients story.
Change from last year, and the maker
How spending and usage moved versus last year, and the company behind each drug, so any change traces back to a maker.
Drug spending always goes up, but the headline never says whether prices rose or more people just filled prescriptions. The records hold the answer, they just aren't built to ask it. So I made it easy to ask.
What people ask about this.
Can you really separate price from how many people use it?
Within the limits of what's published, yes, the records carry the cost per fill and per person right next to the totals, which is exactly what splitting price from usage needs. A drug whose per-fill cost jumped tells a different story than one whose patient count doubled. It's drawn straight from the published figures, not a modeled guess, so the claims stay grounded.
Is this after rebates and discounts?
It reflects the spending as published, before rebates, so you read it as the gross cost picture. That's the most consistent national basis available across drugs and years, and the one most comparisons lean on. Where rebates matter, the gross trend is still the right starting point for spotting which drugs to look at.
How current is the answer?
It stays current on its own. When new information is published, it's already in there, so you're asking against today's picture, not a year-old extract.
Want this pulled apart
for your watchlist?
Whether you're a payer, a researcher, or a policy team, I can get you the exact price-versus-patients answer you care about.